Chemours Company (The) Common Stock (CC)
Stock · NYSE · Industrials
$12.74as of 10/16/2026
Price chart
CC Signal Track Record
How signals performed across all stocks →What CC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -0.7% | 49% | September 15, 2026 |
| Bollinger Band Breakdown | 25 | -4.0% | 48% | September 30, 2026 |
| Bollinger Band Breakout | 21 | -3.5% | 43% | April 24, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -9.2% | 19% | July 23, 2026 |
| Any 20-session window (baseline) | -1.8% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CC
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialt…
- Sector
- Industrials
- Industry
- Major Chemicals
- Employees
- 5,700
- Website
- www.chemours.com/
Fundamentals
- 1-day range
- $12.96$13.39
- Market cap
- $2.27B
- P/E (trailing)
- —
- P/E (forward)
- 6.93
- EPS (trailing)
- $-2.01
- Dividend yield
- 3.79%
- Beta
- 1.48
- Avg. volume
- 2.25M
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- September 15, 2026
How Chemours Company (The) Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Chemours Company (The) Common Stock Competitors
Chosen by industry and closest market cap.
- CCChemours Company (The) Common Stock$12.74▼ 1.32%Market cap $2.27BP/E —$10.44$28.67
- PCTTUPureCycle Technologies Inc. Unit$3.5▲ 0.00%Market cap $2.21BP/E —$3.09$15.49
- MTXMinerals Technologies Inc. Common Stock$62.99▼ 1.19%Market cap $2.34BP/E —$53.94$84.34
- ROGRogers Corporation Common Stock$133.37▼ 3.20%Market cap $2.39BP/E 77.01$75.14$169
- OLNOlin Corporation Common Stock$15.65▲ 0.64%Market cap $2.14BP/E —$14.64$30.46
- NGVTIngevity Corporation Common Stock$69.82▼ 1.02%Market cap $2.66BP/E 44.55$45.85$79.29
- HUNHuntsman Corporation Common Stock$8.58▲ 0.23%Market cap $1.78BP/E —$7.3$16.09
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CC Chemours Company (The) Common Stock | $2.27B | — | $12.74 | ▼ 1.32% | $10.44$28.67 |
| PCTTU PureCycle Technologies Inc. Unit | $2.21B | — | $3.5 | ▲ 0.00% | $3.09$15.49 |
| MTX Minerals Technologies Inc. Common Stock | $2.34B | — | $62.99 | ▼ 1.19% | $53.94$84.34 |
| ROG Rogers Corporation Common Stock | $2.39B | 77.01 | $133.37 | ▼ 3.20% | $75.14$169 |
| OLN Olin Corporation Common Stock | $2.14B | — | $15.65 | ▲ 0.64% | $14.64$30.46 |
| NGVT Ingevity Corporation Common Stock | $2.66B | 44.55 | $69.82 | ▼ 1.02% | $45.85$79.29 |
| HUN Huntsman Corporation Common Stock | $1.78B | — | $8.58 | ▲ 0.23% | $7.3$16.09 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesdaybenzinga · 10/14/2026
- Chemours Q2 2026 Earnings Call: Complete TranscriptBenzinga · 10/8/2026
- UBS Maintains Neutral on Chemours, Lowers Price Target to $16Benzinga · 10/5/2026
- Mizuho Maintains Outperform on Chemours, Lowers Price Target to $18Benzinga · 9/30/2026
- The Dividend Screener Says High Yield. But These Chemical Stocks Tell a Different StoryYahoo · 9/29/2026
- Are Options Traders Betting on a Big Move in Chemours Stock?Yahoo · 9/29/2026
- Lindt cuts 2026 sales growth forecast on weak European chocolate demandYahoo · 9/29/2026
- Kronos Worldwide: Benefiting From Sulfur ShortageSeekingAlpha · 9/23/2026
- Did Chemours' (CC) US$455 Million PFAS Deal Just Reframe Its Long‑Term Liability Narrative?Yahoo · 9/17/2026
Insider Activity
Insider Actions →- Courtney Mather · September 30, 2026 · Grant2.1K @ $13.57
- David Will · August 12, 2026 · Tax Withholding2.4K @ $15.24
- Calderon Gerardo Familiar · August 12, 2026 · Buy1.9K @ $15.53
- Denise Dignam · August 11, 2026 · Buy3.4K @ $14.95
- Joseph T. Martinko · August 7, 2026 · Buy1.9K @ $15.47
- Mary B. Cranston · August 7, 2026 · Buy6.0K @ $15.83
- Alister Cowan · August 7, 2026 · Buy13.0K @ $15.62
- Michael Robert Foley · August 7, 2026 · Buy1.9K @ $15.51
- Shane Hostetter · August 6, 2026 · Buy3.4K @ $14.94
- Shane Hostetter · August 6, 2026 · Tax Withholding3.1K @ $15.11
- Joseph T. Martinko · August 1, 2026 · Tax Withholding663 @ $16.61
- Denise Dignam · August 1, 2026 · Tax Withholding477 @ $16.61
- Kristine M. Wellman · August 1, 2026 · Tax Withholding391 @ $16.61
- Calderon Gerardo Familiar · August 1, 2026 · Tax Withholding943 @ $16.61
- Courtney Mather · June 30, 2026 · Grant1.4K @ $20.52
Institutional Ownership
March 31, 2026
- Total shares held
- 123.40M
- Total value held
- $2.60B
- Institutional holders
- 445
- Unknown22.39M
- Unknown6.77M
- Unknown6.12M
- Unknown5.13M
- Unknown4.84M
- Unknown4.42M
- Unknown3.60M
- Unknown3.10M
- Unknown3.01M
- Unknown2.77M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut
Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.